{"id":49286,"date":"2026-08-01T03:45:00","date_gmt":"2026-08-01T01:45:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=07a276f0b389c99045069e265ca2b965"},"modified":"2026-08-01T03:45:00","modified_gmt":"2026-08-01T01:45:00","slug":"caredx-announces-inducement-grants-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=49286","title":{"rendered":"CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<p>BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) \u2014 a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company\u2019s newly appointed Executive Advisor, certain stock awards as an inducement material to Mr. McNally\u2019s employment with CareDx.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260731951215\/en\/2559419\/5\/CareDx_updated_logo_2025.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260731951215\/en\/2559419\/22\/CareDx_updated_logo_2025.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260731951215\/en\/2559419\/5\/CareDx_updated_logo_2025.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260731951215\/en\/2559419\/21\/CareDx_updated_logo_2025.jpg\" \/><\/a><p>\nCareDx granted 15,822 shares of common stock restricted stock units (RSUs) to Mr. McNally. The RSU awards were made pursuant to the Company\u2019s 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p><p>\n50% of the RSUs will vest on January 2, 2027, and 50% will vest on July 2, 2027 subject to the employee\u2019s continued service through each vesting date.<\/p><p>\nCareDx is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p><p>\n<b>About CareDx<\/b><\/p><p>\nCareDx is a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, CareDx is dedicated to improving patient outcomes. For more information, please visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.caredx.com%2F&amp;esheet=54581023&amp;newsitemid=20260731951215&amp;lan=en-US&amp;anchor=www.caredx.com&amp;index=1&amp;md5=f79882f5a4cfb1ca775ba682ca9e3826\" rel=\"nofollow\" shape=\"rect\">www.caredx.com<\/a>.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nCareDx\n<br\/>Media Contacts\n<br\/>Natasha Moshirian Wagner\n<br\/><a  href=\"mailto:nwagner@caredx.com\" rel=\"nofollow\" shape=\"rect\">nwagner@caredx.com<\/a><br\/>\n<br\/>Investor Relations\n<br\/>Nina Deka\n<br\/><a  href=\"mailto:investor@caredx.com\" rel=\"nofollow\" shape=\"rect\">investor@caredx.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>BRISBANE, Calif.&#8211;(BUSINESS WIRE)&#8211;CareDx, Inc. (Nasdaq: CDNA) \u2014 a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company\u2019&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-49286","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/49286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49286"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/49286\/revisions"}],"predecessor-version":[{"id":49287,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/49286\/revisions\/49287"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}